[Ip-health] How can we ensure public return on public investment? Access to innovation in the context of Covid-19 23 June 2020, 11 – 12 Uhr

Jaume Vidal jaume at haiweb.org
Wed Jun 17 03:45:06 PDT 2020

Dear colleagues,

I hope you are well by the time you read this.

I am pleased to inform you  that Health Action International (HAI) and Universities Allied for Essential Medicines (UAEM) Europe will be hosting an online discussion on the need for new ways to harness innovation and promote access to medicines within and beyond the current market oriented, patent-centered model.

In the context of the challenges exacerbated by the COVID-19 pandemic, we will look at the latest developments in Europe, with specific focus on Germany, while considering the resources included in HAI’s publication “Guidelines for Socially Responsible Management of Innovation” which we will relaunch for the occasion. Reference will be made to recent developments in knowledge governance  in other EU member States like Spain, Netherlands or Italy.

For the last decade, Germany has witnessed an animated debate between academics, advocates and policy makers around how best articulate public-generated knowledge and industrial policies, including the development and manufacturing of medicines. This discussion is gaining new traction with the occurrence of shortages of medicines and the need to respond to a health crisis.

As a leading player in the European Union (EU) health policy debate and as the country about to take up the Presidency of the European Council,  Germany can make a strong case for a socially responsible response to COVID-19, as well as to other obstacles affecting access to medicines.

This discussion will bring together a diverse audience to exchange ideas on the importance of access to innovation in Germany, and the wider EU, grounding the debate in the responsibility of government, public authorities, universities and public research institutions to ensure public return on public investment.

Introductory remarks
- Christian Wagner-Ahlfs Expert on equitable licensing, main author of Leitfaden für sozial-verträgliche Verwertung. Forschungsergebnisse für möglichst viele Menschen nutzbar machen
Confirmed panelists:
-Dr. Victoria Chege, Lecturer of European Business Law, Carl von Ossietzky University
-Prof. Dr. Christine Godt, Professor of European and International Business Law, Carl von
Ossietzky University Oldenburg
-Jaume Vidal, Senior Policy Advisor Health Action International
-Paul Schnase, Universities Allied for Essential Medicines

How can we ensure public return on public investment?: Access to innovation in the context of Covid-19
23 June 2020, 11 – 12 Uhr
Register at https://bit.ly/publicreturn_corona
The event will be held in German and English. Unfortunately, we can't provide translation.

Feel free to disseminate/share/forward


Senior Policy Advisor, European Projects
Health Action International
During the Coronavirus emergency
Working days Monday to Friday<%20%20> mornings  (830/1530)
T: +31 (0) 20 412 4523 | M: +31 6 2831 8884 | +34 727 787 913
Overtoom 60 (2) | 1054 HK Amsterdam | The Netherlands
EU Transparency Register: 44361352681-84

More information about the Ip-health mailing list